Bankruptcy Court OKs Correlogic Motion to 'Reject' Quest, LabCorp Pacts | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A Bankruptcy Court today approved Correlogic System's motion to "reject" licenses the molecular diagnostics firm had with Quest Diagnostics and Laboratory Corporation of America as part of its Chapter 11 reorganization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.